FindTrial
Sign In

Effective site concentration of remifentanil inhibiting hypertension following endotracheal intubation using videolaryngoscope during induction with remimazolam

Effective site concentration of remifentanil inhibiting hemodynamic response following endotracheal intubation using videolaryngoscope during induction with remimazolam

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0008697
Enrollment
34
Registered
2023-08-10
Start date
2023-07-13
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Bundang CHA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Korean patients between the ages of 19 and 65 who are classified as American Society of Anesthesiology Classes 1 and 2 under general anesthesia

Exclusion criteria

Exclusion criteria: Allergy to study drug, acute narrow-angle glaucoma, sleep apnea syndrome, alcohol or drug dependence, galactose or lactase deficiency, dextran 40 hypersensitivity, heart, lung, kidney, liver, cerebrovascular system, Psychiatric patients, pregnant women, lactating women, foreigners, others American Society of Anesthesiologists Body Classification 3 or higher

Design outcomes

Primary

MeasureTime frame
Effective site concentration of remifentanil (EC95) that secures hemodynamic stability in 95% of patients after endotracheal intubation (blood pressure or heart rate measured 1 minute after endotracheal intubation do not rise by more than 20% of the reference value)—

Secondary

MeasureTime frame
Effective site concentration of remifentanil (EC50) that secures hemodynamic stability in 50% of patients after endotracheal intubation (blood pressure or heart rate measured 1 minute after endotracheal intubation do not rise by more than 20% of the reference value)—

Countries

Korea, Republic of

Contacts

Public ContactJiyoung Lee

Bundang CHA General Hospital

jlee0616@cha.ac.kr+82-31-780-5157

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Jun 27, 2026